Canaccord Genuity Reiterates Buy on Map Pharmaceuticals (MAPP)
Map Pharmaceuticals traded up 0.17% on Monday, hitting $11.95. Map Pharmaceuticals has a 1-year low of $10.54 and a 1-year high of $17.92. The company’s market cap is $365.9 million.
Other equities research analysts have also recently issued reports about the stock. Analysts at JPMorgan Chase (NYSE: JPM) cut their price target on shares of Map Pharmaceuticals from $23.00 to $22.00 in a research note to investors on Monday. Separately, analysts at TheStreet downgraded shares of Map Pharmaceuticals to a “sell” rating in a research note to investors on Thursday, April 12nd. Finally, analysts at Ladenburg Thalmann reiterated a “buy” rating on shares of Map Pharmaceuticals in a research note to investors on Wednesday, March 28th. They now have a $24.00 price target on the stock.
MAP Pharmaceuticals, Inc. is a development-stage company. The Company focuses on advancing its Phase III product candidate, LEVADEX orally inhaled migraine therapy, formerly MAP0004, an orally inhaled version of dihydroergotamine mesylate (DHE), for the potential treatment of migraine.